Patient-derived tumour organoids (PDOs) have revolutionised our understanding of cancer
biology and the applications of personalised therapies. These advancements are principally …

Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has
broadened the repertoire of preclinical models and progressively revolutionized three …

The emergence of three-dimensional human organoids has opened the door for the
development of patient-derived cancer organoid (PDO) models, which closely recapitulate …

Background Organoid technology is an emerging and rapidly growing field that shows
promise in studying organ development and screening therapeutic regimens. Although …

Cancer is associated with a high degree of heterogeneity, encompassing both inter-and
intra-tumor heterogeneity, along with considerable variability in clinical response to common …

Cancer therapy is on the brink of a significant transformation with the inclusion of patient-
derived organoids (PDOs) in drug development. These three-dimensional cell cultures …

In the era of precision medicine, cancer researchers and oncologists are eagerly searching
for more realistic, cost effective, and timely tumor models to aid drug development and …

Simple Summary Currently, organoid research is having a growing impact in oncology.
Tumor organoids, directly derived from patients' specimens, can easily be expanded and …

Cancer represents a leading cause of death, despite the rapid progress of cancer research,
leading to urgent need for accurate preclinical model to further study of tumor mechanism …

Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that
stably retain key characteristics of the respective organs. Organoids can be generated from …